Clinical Trial Update: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial sponsored by OHSU Knight Cancer Institute is evaluating a five-drug combination (venetoclax, dasatinib, prednisone, rituximab, and blin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Phenotype Acute Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)
• PREDNISONE (Prednisone)
• Rituxan (rituximab)
• Sprycel (dasatinib)
• Venclyxto (Venetoclax)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Status: RECRUITING